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Abstract
Background: Diabetic nephropathy (DN) is a major complication of type1 and type 2 diabetes. Understanding how
diabetes regulate transcriptome dynamics in DN is important for understanding the biology of the disease and for
guiding development of new treatments.
Results: We analyzed the kidney transcriptome of a DN mouse model, D2.B6-Ins2Akita/MatbJ, before/after treatment
with P78-PEDF. Age, weight, and gender-matched mice and wild-type (wt) littermates were treated at 6 weeks
(early treatment) or 12 weeks (late treatment) of age for the duration of 6 weeks. Animals were implanted with an
osmotic mini pump delivering 0.3 ug/g/day P78-PEDF or vehicle. Using RNA-seq, we identified14,316 transcripts
(12,328 coding;1,988 non-coding) that were significant and reliably expressed (FPKM > =1) in diabetic kidneys.
Expression of 1,129 (7.9%) including 901 coding genes was altered by diabetes with log2 fold changes (FC)
between -86.2 and +86.0 (q < 0.05) compared to wt. Of these, 164 (14.5%) showed increased and 965 (85.5%)
decreased expression with FC > 1.5. Coding genes with highest FC in diabetic kidneys include Nhej1 (32.04), Ept1
(8.6), Srd5a2 (-6.55), Aif1 (-6.05), and Angptl7 (-4.71).
Early and late stage diabetic groups receiving continuous infusion of P78 showed altered expression of 316/14,316 (2.2%)
transcripts, including 121 coding genes compared to non-treated diabetic controls. Of these, 183 were upregulated and
133 downregulated with FC +50.9–-93.3 (q < 0.05). P78 reversed diabetes-induced changes in 138/1129 (12.2%)
transcripts, including 49/901 (5.44%) coding genes. Nhej1 (-37.94), Tceanc2 (5.76), Ept1 (-4.45), Ugt1a2 (3.03), and
Tmsb15l (-3.0) showed the highest FC with treatment. The DNA repair gene, Nhej1 with the greatest FC in diabetic
kidneys was completely restored to control levels by both early and late P78 treatments. Expression of other coding
genes regulated by diabetes with FC > =(+/-) 1.5 and completely reversed by P78 include Mamdc4, Kdm4b, Tmem252,
Selm, and Hpd. RT and QRT-PCR validated expression of gene with FC > (+/-)2.0. Transcriptome changes were also
observed between early and late-stage treatments.
Precursor non-coding miRNAs showed the highest fold changes in expression in the diabetic and P78 treatment
groups. Several diabetic-induced changes were reversed in direction of expression by treatment including Gm24083,
GM25953, miR1905, Gm25535, Gm27903, and miR196a1 with FC > =(+/-)20.
From Ingenuity pathway analysis (IPA), mitochondrial dysfunction, Nrf-2- mediated oxidative stress and renal injury
pathways emerged as key mechanisms in DN. DN-enriching genes in these pathways were reduced in number or
regulated in the opposite direction by treatment.
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Conclusions: Unique biomarkers and canonical pathways identified in this study may hold the key to understanding
mechanisms of DN pathobiology with value for clinical translation. Our data suggest that mitochondrial dysfunction,
genotoxicity and oxidative stress are principal events in DN and that P78-PEDF holds promise for its management.
Keywords: Diabetic nephropathy, PEDF P78 peptide, Global transcriptome changes, RNAseq, Canonical pathways,
miRNA, Nhej1, Ept1, Mamdc4, Kdm4b
Background
The prevalence of diabetes in the world has been esti-
mated at 2.8% in 2000, and is projected to increase to
4.4% by 2030 [1]. The disease currently affects approxi-
mately 8.3% of the US population, and is a leading
cause of morbidity and mortality. Diabetes is a major
cause of stroke, blindness, heart disease, and end-stage
renal disease (ESRD) [2]. Among these sequelae, dia-
betic nephropathy (DN) is one of the most common
complications of both Type 1 and Type 2 diabetes [3].
The pathophysiology of DN is complex and multiple
mechanisms contribute to its development and outcome.
Early hemodynamic changes and defective autoregulation
of glomerular filtration rate lead to glomerular hyperfiltra-
tion and hyperperfusion [4]. Mechanisms involving glyco-
sylation of tissue proteins [5], activation of Protein kinase
C [6], and the Aldose reductase pathway [7] are believed
to promote tissue damage, glomerular basement mem-
brane thickening, glomerular hypertrophy and mesangial
expansion. Other factors linked to the development and
progression of DN include the expression of nephrin [8],
inflammatory cytokines, vascular endothelial growth factor
(VEGF) [9], lipid mediators [10], and reactive oxygen
species [11]. Although, there is evidence that genetic pre-
disposition influences the incidence and severity of DN,
the low likelihood of identifying a single gene for the
pathogenesis of DN has shifted research towards a multi-
gene approach to understand mechanisms and etiology of
the disease [4].
Current management of DN centers on preventing the
development of risk factors such as hypertension, hyper-
glycemia, and dyslipidemia, early diagnosis, and antihyper-
tensive therapy to reduce rate of decline in renal function
[12]. Despite advancements in therapy, DN continues to
be the most common cause of ESRD and requires dialysis
in the U.S. [3]. The human and economic costs associated
with ESRD raise the importance of risk factor reduction
and the need to identify novel therapeutic targets to man-
age diabetes-induced kidney damage.
A large number of studies have now documented the pro-
tective role of pigment epithelium-derived factor (PEDF)
against a wide range of oxidative and excitotoxic insults
[13–15]. The neuroprotective, anti-angiogenic and anti-
inflammatory properties of PEDF have been exploited
in many preclinical therapeutic strategies [13] especially
since the gene is expressed in several tissues [16] in-
cluding the kidney where the highest expression is in
the glomeruli [17]. In diabetes, serum levels of PEDF
increase whereas tissue levels in the eye and kidney de-
crease in diabetic retinopathy and diabetic nephropathy
respectively [18–20]. Such studies imply that restoring
PEDF levels could reduce damage to tissues in diabetes.
For example, increasing PEDF levels in the kidney by
injecting an adenovirus expressing the protein signifi-
cantly alleviates microalbuminuria in the early stages of
diabetes [21].
Because PEDF is a large 50kD protein it has limited
usefulness as a therapeutic agent in many cases. However,
an active 44 amino acid fragment of PEDF (P78-PEDF) can
block ischemic damage to retinal ganglion cells and reduce
neuronal death, vascular abnormalities and inflammatory
changes in a mouse model of diabetic retinopathy [22, 23].
We have shown that continuous infusion of this peptide in
diabetic mice protects against development of diabetic
nephropathy as indicated by reduced albuminuria, blood
urea nitrogen, macrophage recruitment and expression of
inflammatory cytokines and fibrotic markers, balanced
nephrin expression, and decreased histological changes in
diabetic kidneys [24]. In a proof of concept extension of
those studies we confirmed that continuous systemic infu-
sion of P78 blocks the progression of well-established dia-
betic nephropathy in the Ins2Akita mouse model of DN
[25]. Here we used kidney samples obtained from the re-
cently published proof of concept experiments [25] to
study transcriptome changes in these non-treated and
P78-treated diabetic nephropathy mice to identify novel
gene candidates and pathways as regulators in the patho-
genesis of DN.
Methods
P78 drug delivery in diabetic Ins2Akita mice
Kidney tissue samples were obtained from a recently
published study that tested physiological effects of P78
on kidney function and pathology [25]. Animals were
treated as previously described [25] prior to extracting
RNA for RNA-seq analysis. The animal studies were ap-
proved by the Penn State University College of Medicine
Institutional Animal Care and Use Committee, and per-
formed in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of
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the National Institutes of Health. All experiments were
conducted using male D2.B6-Ins2Akita/MatbJ diabetic
animals and their wild type (WT) littermate mice (DBA/2 J
background), recommended by the Animal Models of
Diabetes Complications Consortium (AMDCC) as a model
of DN [26, 27]. The diabetic D2.B6-Ins2Akita mice develop
hyperglycemia at 3 weeks of age and all treatment carried
out when the mice were either 6 weeks (3 weeks hypergly-
cemic exposure; early stage treatment) or 12 weeks (9 weeks
hyperglycemic exposure; late stage treatment) of age. Only
mice with blood glucose levels > 350 mg/dl (measured
using Accu-Chek glucometer, Boehringer Mannheim,
Indianapolis, IN) were considered diabetic and used in
the study.
The drug tested was P78, a small PEDF active peptide
[22, 23], generated by methods previously described
[25, 28]. Briefly, P78 peptide at a dose of 0.3 μg/g/day
or vehicle (phosphate-buffered saline; PBS) was adminis-
tered by continuous subcutaneous infusion via the osmotic
minipump (no. 2006; Alzet, Durect, Palo Alto, CA), im-
planted dorsally between the shoulders of the animals as
previously described [25, 29–31]. Transcriptome analysis of
wild-type and diabetic kidney samples were performed at
two stages of diabetes where treatment was initiated at an
early stage (6 weeks of age; 3 weeks hyperglycemic) and late
stage (12 weeks of age; 9 weeks hyperglycemic). Age, gen-
der, and weight matched diabetic Ins2Akita and wild-type
non-diabetic controls were used in the study. All animals
including wild-type were implanted with an osmotic mini-
pump infused with either vehicle (wt and diabetic controls)
or the P78 peptide (diabetic mice). Duration of treatment
was 6 weeks with either peptide or vehicle. One group re-
ceived treatment at the early stage of diabetes (ET, early
treatment) at 6 weeks of age and the experiment termi-
nated at 12 weeks of age. Treatment in the second group
was initiated at late stage diabetes (LT, late treatment) at
12 weeks of age and terminated at 18 weeks of age. Mice
were provided ad lib access to food and water and were
euthanized at the end of the experimental period. Kidney
samples for RNA extraction were immediately harvested
and frozen in liquid nitrogen at the termination of the
experiment.
Tissue samples preparation and RNA isolation
For RNAseq we used 13 kidney tissue samples from
wild-type mice, 7 from the diabetic Ins2Akita mice, 8
from early P78 treatment of diabetic Ins2Akita mice, and
7 from late P78 treatment the diabetic Ins2Akita mice
[25]. Total RNA was extracted using mirVana kit (Life
Technologies) with some modifications. Briefly, a bead
mill homogenizer (Bullet Blender, Next Advance) was
used to homogenize the tissue using a safe-lock micro-
centrifuge tube (Eppendorf ) and a mass of stainless
steel beads (Next Advance, cat# SSB14B) equal to the
mass of the tissue. Immediately after two volumes of
lysis buffer were added to the tube, samples were mixed
in the Bullet Blender for 1 min at a speed of six. Samples
were visually inspected to confirm desired homogenization
and then incubated at 37 °C for 5 min. The lysis buffer was
added up to 0.6 ml, and samples were mixed in the Bullet
Blender for 1 min. Optical density values of extracted RNA
were measured using NanoDrop (Thermo Scientific) to
confirm an A260:A280 ratio above 1.9. RNA integration
number (RIN) was measured using BioAnalyzer (Agilent)
RNA 6000 Nano Kit to confirm RIN above 7.
Library preparation and sequencing
The cDNA libraries were prepared using SureSelect
Strand Specific RNA Library Preparation Kit (Agilent) as
per the manufacturer’s instructions. Briefly, polyA RNA
was purified from 1000 ng of total RNA using oligo (dT)
beads. Extracted RNA was subjected to fragmentation,
reverse transcription, end repair, 3’-end adenylation,
adaptor ligation and subsequent PCR amplification and
SPRI bead purification (Beckman Coulter). The unique
barcode sequences were incorporated in the adaptors for
multiplexed high-throughput sequencing. The final product
was assessed for its size distribution and concentration
using BioAnalyzer High Sensitivity DNA Kit (Agilent) and
Kapa Library Quantification Kit (Kapa Biosystems). 12
libraries were pooled and diluted to 2 nM in EB buffer
(Qiagen) and then denatured using the Illumina protocol.
The denatured libraries were diluted to 10 pM by pre-
chilled hybridization buffer and loaded onto TruSeq SR v3
flow cells on an Illumina HiSeq 2500 and run for 50 cycles
using a single-read recipe (TruSeq SBS Kit v3) according
to the manufacturer's instructions (Illumina).
Quality control, mapping and quantification of RNA-Seq
reads
Illumina CASAVA pipeline Version 1.8 was used to extract
de-multiplexed sequencing reads. FastQC (version 0.11.2)
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/)
was used to validate the quality of the raw sequence data.
Additional quality filtering used FASTX-Toolkit (http://
hannonlab.cshl.edu/fastx_toolkit) using a quality score
cutoff of 20. Next, alignment of the filtered reads to the
mouse reference genome (mm10) was done using Tophat
(version 2.0.9) [32] allowing 2 mismatches. Picard (ver-
sion1.102) (https://github.com/broadinstitute/picard) was
used to assess proportion of mapped bases to coding,
UTR, intronic, and intergenic regions, respectively. Picard
was used to find coverage across gene body to determine
5’- or 3’- bias. FPKM (Fragments Per Kilobase of Exon Per
Million Fragments Mapped) values were calculated using
Cufflinks Version 2.0.2 [33] as provided with the Ensembl
gene annotation (release 78).
Rubin et al. BMC Genomics  (2016) 17:936 Page 3 of 17
Differential Gene Expression (DEG) analysis
Only reliably expressed genes were included in the ana-
lysis, defined to be those with at least 2 samples with
FPKM > = 1. The ComBat function of the sva v3.10.0 R
package was used for batch normalization of the FPKM
values. The DEGexp function of the DEGseq v1.18.0 R
package [34] was used to identify differentially expressed
genes (DEG) between diabetes and control (DvC), treat-
ment and diabetes (TvD), early treatment and diabetes
(ETvD) and late treatment and diabetes (LTvD), using
the Likelihood Ratio Test method. Significantly DEG
were defined to be those with q-value < 0.05 calculated
by the Storey et al. 2003 method.
Visualization
The batch adjusted RNA-seq FPKM values of the reli-
ably expressed genes were averaged for samples in each
category: C, D, ET and LT. A heatmap of the Z scaled
resulting FPKM values was generated using the heat-
map.2 function of the gplots R package, with parameters
“average” for clustering method and 1-correlation for
distance. The Z scaling was performed with the genefil-
ter v1.46.1 R package. A volcano plot was generated of
the –log10(p-value) vs. log2(normalized FC) of the DvC
and TvD DEG analyses, with points with q < 0.05 and
abs(log2(normalized FC)) > = 1 (i.e. a FC threshold of 2)
colored red for DvC and green for TvD. Labeled genes
have a q-value < 0.05 and abs(log2(normalized FC)) > = 2
(i.e. a FC threshold of 4). Quad Venn diagrams showing
the number of significant DEG genes and protein coding
subsets for various comparisons were generated using
the VennDiagram v1.6.9 R package.
Functional analysis
The Tox Analysis function of Ingenuity Pathway Analysis
(IPA) (QIAGEN, California) was used to create gene sets
based on biological processes and toxicological responses
to xenobiotic insult using the mammal filter (human, rat,
mouse) and the following tissues in turn: adipose, brain,
heart, kidney, liver, retina and all tissues. IPA Build 2015-
03-23.
Statistical analysis
Statistical tools embedded in the previous instruments
and statistical packages were applied. Significant DEG
were defined to be those with q-value <0.05 calculated
by the Storey et al. 2003 method.
RT-PCR
Total mRNA from treated, non-treated, and wt kidney
samples was extracted for PCR using the RNAeasy Mini
Kit (Qiagen) First-strand cDNA of isolated mRNA was
synthesized using Superscript First Strand cDNA Syn-
thesis reagents (Invitrogen). Gene-specific primers were
designed using NCBI Primer-Blast primer design tool
(Primer3web version 4.0.0) and primer information listed
in the table below. Reverse transcription (RT)-PCR was
carried out using 80 ng cDNA from pooled samples, PCR
master mix reagents (Invitrogen), annealing temperature
of 58 °C, and 35 amplification cycles. PCR products were
resolved by 1% agarose gel electrophoresis. Quantitative
RT-PCR (qrt-PCR) was also performed using 20 ng cDNA
and these primers to cross-validate, quantitate, and con-
firm gene expression changes and trends. For qrt-PCR, a
two-step amplifying protocol was used with iQ SYBR
Green Supermix solution (Bio-Rad). Ct (threshold cycle)
was used to determine gene expression levels.
Results
Global transcriptome changes
Results obtained from DEGseq analysis applied on RNA-
seq FPKM (Fragments per kilobase of exon per million
Genes ENSEMBL # Primer sequence (5’-3’) Amplicon size (bp)
Nhej1 ENSMUSG00000026162 F: 5’ CCAAGCACGGTTATGCCTTG 3’
R: 5’ CAGGCTCACACCCATCAGAG 3’
344
Ept1 ENSMUSG00000075703 F: 5’ TTCAGCCAGAGATGCCAGTG 3’
R: 5’ CAGGCACCCAATCCTAGCAA 3’
274
Cyp4a14 ENSMUSG00000028715 F: 5’ TTGCCAGAATGGAGGATAGGAA 3’
R: 5’ TGGAGCGTCCATCTGGGAAG 3’
324
Ugt1a2 ENSMUSG00000090171 F: 5’ GCCCCTTCGAGGAATCTCAG 3’
R: 5’AGGTCTTCTCAATGTCGCTCAG 3’
278
KDM4B ENSMUSG00000024201 F: 5’ TCCACCAACACCCCTCAATG 3’
R: 5’ AAGGGGTTGTTCCCTGTGAG 3”
218
Selm ENSMUSG00000075702 F: 5’ CACCAACTACCGACCGGATT 3’
R: 5’ TCCTGTACCAGCGCATTGAT 3’
261
Mamdc4 ENSMUSG00000026941 F: 5’ GCTCCTGGGCACTTCCTATC 3’
R: 5’ GAGTCACATTGTCCACCCCA 3’
334
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fragments mapped) showed significant differences in coding
and non-coding genes expressed in the kidney among con-
trol (C, wild-type), diabetic (D), early (ET), and late (LT)
P78 treatment in the Ins2Akita mouse model of diabetic
nephropathy (DN). Below we provide results for protein
coding and non-coding genes that were regulated in the
diabetic kidney relative to P78 treated and wt controls: The
comparisons are (1) diabetic relative to wild type (DvC), (2)
P78 treated relative to non-treated diabetic (TvD), (3) dia-
betic returned to normal levels by treatment (early and late
stage treatment), and (4) P78 early stage treatment (ET)
compared to late stage treatment (LT). Early (ET) and late
(LT) P78 treatments are grouped in the TvD analyses to de-
termine all gene targets of the treatment whether given at
early or late stages of diabetes. These are later separated in
the study to determine those targets that were unique to
ET and those unique to LT.
Global expression changes
The heatmap in Fig. 1 and volcano plot in Fig. 2 show glo-
bal transcriptome changes in control, diabetic, and P78
early and late treatments in kidney tissues of the Ins2Akita
mouse model of diabetic nephropathy. 43,168 RNA tran-
scripts were identified in the kidney. 25,254 had an FPKM
value > 0 and 14,316 were considered reliably expressed,
defined to be those with FPKM> =1. Of the 14,316 reli-
ably expressed sequences, 12,328 were protein coding
genes and 1,988 non-coding RNA transcripts.
The distribution of all genes (protein-coding and non-
coding) with respect to significance (y axis) versus fold
changes (x axis) is shown in the scatter plot in Fig. 2
(–log10(p-value) vs log2(normalized fold change (FC)).
Genes of interest are outside the midline where abso-
lute normalized FC > =(+/-)4 are colored red for DvC
(diabetic versus wt controls) and green for TvD (early
and late stage P78-treated diabetic mice versus diabetic con-
trols). A few genes including Nhej1, Ept1, Cyp4a14, and
Ugt1a2, which are significantly regulated by diabetes and
treatment with an absolute normalized FC > =(+/-)4,
are labeled as examples to show their location and rela-
tionship to other points in the plot and to the midline.
Many protein-coding and non-coding genes showed small
Fig. 1 Heatmap of Z scaled RNA-seq FPKM (Fragments per kilobase of exon per million fragments mapped) values of 14,316 reliably expressed
transcripts in kidney samples of the Ins2Akita mouse model of diabetic nephropathy (DN). FPKM values were averaged for samples in each
category (C: control, D: diabetic, ET: early P78 treatment, LT: late P78 treatment) (n = 7-13)
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changes in their expression levels in either direction but
only those that met our selection criteria of FC > =(+/-)1.5,
q < 0.05 were of interest in this study and rank-ordered in
all tables according to fold changes in either direction.
All transcripts regulated by diabetes and P78
Gene expression differences in the kidney between the
diabetic compared to control (DvC) and P78 treatment
compared to diabetic (TvD, early and late) groups are
shown in the Venn diagram in Fig. 3 and in Table 1.
These represent all protein-coding and non-coding
RNA transcripts that showed statistically significant dif-
ferential expression (DEG) (q < 0.05). Changes in ex-
pression levels were seen in 1237 transcripts in the
kidney (a total of all numbers in the Venn diagram).
208 (46 + 51 + 87 + 24) of these were regulated by both
diabetes and treatment. 1,129 RNA transcripts (coding
plus non-coding) were regulated by diabetes with log2 fold
changes (FC) ranging between -86.2 and +86.0 (q < 0.05)
(Table 1). 164 were upregulated and 965 downregulated
by diabetes. P78 treatment (early and late; TvD group) al-
tered expression of 316 transcripts with FC between -93.3
and +50.9 (q < 0.05). Of these, 183 were upregulated and
133 downregulated. A total of 138/1129 (12.2%)
transcripts whose levels were either increased (51 tran-
scripts) or decreased (87 transcripts) by diabetes were re-
versed in the direction of their expression to normal levels
by P78 treatment (Table 1). While the regulation of most
transcripts by diabetes were not reversed by treatment,
the effects of P78 in reducing pathology and progression
of DN that we have previously shown [24, 25] may be due,
in part, to reversing diabetes-induced expression
changes in this subset (138) of coding and non-coding
RNA transcripts.
Protein-coding genes (mRNA) regulated by diabetes and
P78
Figure 4 and Table 2 show the number of protein coding
genes (mRNA) regulated by diabetes and P78. Changes
in gene expression occurred in 934 protein-coding genes
(all numbers in the Venn diagram) in the kidney of the
Ins2Akita mouse model of DN, with 88 of these (33 + 15 +
34 + 6) regulated by both diabetes and treatment. Diabetes
altered expression of 901 genes (q < 0.05), of which 71 were
upregulated and 830 downregulated by the disease (Table 2).
P78 (early and late treatment) modulated expression of 121
coding genes with 65 of these showing increased and 56
showing decreased expression levels. P78 treatment
Fig. 2 Volcano Plot showing –log10(p-value) vs log2(normalized fold change (FC)) of RNA-seq FPKM (Fragments per kilobase of exon per million
fragments mapped) for all transcripts (protein-coding and non-coding) differentially expressed genes (DEG) in kidney samples of Ins2Akita mouse
model of diabetic nephropathy. Distribution of genes with respect to significance (y axis) versus fold changes (x axis) is shown. Genes of interest
outside the midline where absolute normalized FC > =+/-4 (q < 0.05) are labeled as examples to show changes in expression levels in diabetic
(DvC, Red) or P78 treated diabetic mice (TvD, Green) relative to controls. Horizontal dashed line represents expression value p = 0.05; above
line p < 0.05; below line: p > 0.05. Genes outside the midline have FC > 1
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reversed direction of expression of 49/901 (5.44%) of the
protein coding genes regulated in diabetic kidneys towards
normal levels (Table 2).
Only protein-coding genes with the highest fold changes
induced by diabetes or P78 are shown in Table 3A-C.
These represent all differentially expressed genes with
absolute FC > =(+/-)1.5 (q < 0.05) and are rank-ordered by
FC in either direction. Table 3A lists protein-coding genes
that were regulated by diabetes of which Nhej1 (+32.04),
Ept1 (+8.6), Srd5a2 (-6.55), Aif1 (-6.05), Angptl7 (-4.71),
Thrsp (-4.57), Cyp4a14 (+4.4), Ucp1 (-4.35), Atf7ip
(+4.21), Lypd2 (-4.2), and Ugt1a2 (-4.13) had FC > (+/-)4.0
(q < 0.05).
Table 3B lists genes (FC > =(+/-)1.5 in diabetic animals
that showed changes in expression by P78 treatment
(early and late) of which the top 5 include Nhej1 (-37.94),
Tceanc2 (+5.76), Ept1 (-4.45), Ugt1a2 (+3.03), and
Tmsb15l (-3.0) with FC > (+/-)3.0 (q < 0.05).
P78 Treatment normalized gene expression altered by
diabetes
From this analysis (Table 3A and 3B), we identified a
small set of genes where the changes in diabetes were
substantially (~50%) or completely reversed by P78
treatment. These are listed in Table 3C and rank-ordered
by FC > =(+/-)1.5 (q < 0.05). Of these, non-homologous
end-joining factor 1 (Nhej1) had the highest absolute fold
change in expression with both diabetes and treatment.
Diabetes induced expression levels of Nhej1 by +32.04
while P78 complete reversed expression by -37.94 fold
Fig. 3 The Venn Diagram shows RNA-seq data for all RNA biotypes (protein-coding and non-coding) that were regulated by diabetes compared
to control (DvC) and by P78 treated compared to non-treated diabetic controls (TvD). FC: fold changes. Blue: DvC - positive FC (FC > 0). Green:
DvC - negative FC (FC < 0). Pink: TvD - positive FC (FC > 0). Yellow: TvD - negative FC (FC < 0). Changes in expression levels were seen in 1237
transcripts of which 208 were regulated by both diabetes and treatment. 1129 transcripts were regulated in DN, 316 by treatment (early and late),
and 138 whose expression levels were altered in DN were reversed by treatment towards control levels (q < 0.05)
Table 1 Number of all transcripts (coding and non-coding) that
were significantly regulated in the kidney by diabetes (D), P78
treatment (T, early and late treatment), and those with expression
changes in D that were reversed by T in the Ins2Akita mouse model
of diabetic nephropathy (DN) (q < 0.05)
Group # of Genes
Upregulated in D 164
Downregulated in D 965
Upregulated with T 183
Downregulated with T 133
Upregulated in D, reversed by T 51
Downregulated in D, reversed by T 87
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changes. Treatment also completely reversed diabetes-
induced expression changes of Mamdc4, Kdm4b, Tmem252,
Selm, and Hpd while others were returned in the direction
of normal levels from their diabetes-induced state by ~50%
(Table 3C).
Regulation of genes with FC > =(+/-)2.0 (q < 0.05) by
diabetes, or treatment (P78 early (ET), and P78 late
(LT)) (Table 3C) was subsequently cross-validated for
trend in expression by RT-PCR and QRT-PCR (Fig. 5)
with the exception of Mamdc4, whose expression level
was below the detection threshold using these PCR con-
ditions. While regulation trends remain the same, some
differences in levels of gene regulation between the RNAseq
and PCR data were noted, which were possible due to pri-
mer specificity, alternatively spliced forms of the genes,
RNA integrity, and/or PCR conditions.
This small subset of genes regulated in opposite direc-
tions by both diabetes and P78, a treatment previously
shown to reduce DN pathology [24, 25] may be critically
involved in diabetes-induced mechanisms that control
the development of the disease.
Transcripts regulated by early and late stage P78
treatment
Since treatments were given at early and late stage dia-
betes, we sorted the data to identify genes that were
regulated by early treatment and those regulated by
late treatment (Table 4). Several transcripts were unique
targets of P78 in early and in late stages of diabetes but
many were common targets of P78 regardless of the stage
of diabetes (Table 4A and 4B) in which case treatment
completely reversed diabetes-induced regulation. Nhej1,
for example showed regulation from FC = +32.0 in the
Fig. 4 The Venn diagram shows RNAseq data for only protein-coding genes that are regulated by diabetes or P78 treatment. Expression changes
were detected in 934 protein-coding genes with 88 regulated by both diabetes and treatment. 901 coding genes were regulated by diabetes,
121 by P78 treatment (early and late) and 49 coding genes with changes induced by diabetes were reversed by treatment toward control levels
of expression (q < 0.05)
Table 2 Number of protein-coding (mRNA) genes that were
significantly regulated in the kidney by diabetes and by P78
treatment compared to non-diabetic controls, and those with
expression changes in diabetes that were reversed towards
normal levels by P78 treatment in the Ins2Akita mice with FC >
(+/-)1 (q < 0.05)
Group # of Genes
Upregulated in D 71
Downregulated in D 830
Upregulated with T 65
Downregulated with T 56
Upregulated in D, reversed by T 15
Downregulated in D, reversed by T 34
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diabetic kidney (Table 3A) to -38.55 and -37.33, for early
and late treatments, respectively (Table 4A, 4B). Nhej1, a
DNA repair gene, showed the highest fold changes of the
protein coding genes regulated by P78 treatments (ET,
LT) in both stages of diabetes. We identified sixteen
protein-coding genes that were targets of P78 that were
significant and reliably altered in expression levels re-
gardless of the diabetic stage when treatment was given
(Table 4B). These represented ~50% similarity in gene ex-
pression changes by treatment at both early and late stages
of diabetes. With the exception of C3, which showed
Table 3 Differentially expressed protein coding genes (mRNA)
showing the highest fold changes (in either direction) in kidney
samples of the Ins2Akita mice in the diabetic (D) and P78
treatment (T) groups
Increased Decreased
Gene Fold change Gene Fold change
A
Nhej1 32.04 Srd5a2 −6.55
Ept1 8.6 Aif1 −6.05
Cyp4a14 4.44 Angptl7 −4.71
A@7ip 4.21 Thrsp −4.57
Foxn3 2.92 Ucp1 −4.35
Txnrd1 2.76 Lypd2 −4.2
Gldc 2.44 Ugt1a2 −4.13
Cyp4a12b 2.4 Ly6e −3.77
Sulf2 2.37 Scd1 −3.7
Kdm4b 2.28 Inmt −3.42
Suco 2.28 Ang −3.24
Cyp4a10 2.27 Cyp2d12 −2.94
Aldh1a7 2.21 Anxa13 −2.92
Slc18b1 2.04 Car9 −2.89
Reep6 1.97 Mamdc4 −2.85
Gsta2 1.95 Cox8b −2.77
Zbtb18 1.94 Tmem86a −2.64
Slc38a3 1.93 Il34 −2.57
Akr1d1 1.91 Ramp3 −2.51
Etf1 1.86 Acsm3 −2.5
ApoB 1.85 Gusb −2.48
Erlin1 1.8 Hsd17b11 −2.43
Pklr 1.78 Cyp4b1 −2.35
Folh1 1.77 Rarres2 −2.32
Cfd 1.71 Lipo1 −2.32
Huwe1 1.7 Nudt19 −2.28
Itgb6 1.69 Cck −2.28
Cyp4a31 1.65 H2-Ab1 −2.27
Mtus1 1.65 Tmem37 −2.22
Selm 1.64 Eri2 −2.2
Ccng1 1.64 C1qtnf3 −2.18
C3 1.61 Rhod −2.18
Enpep 1.6 Stab1 −2.14
Mgst1 1.56 Hsd11b1 −2.13
B
Tceanc2 5.76 Nhej1 −37.94
Ugt1a2 3.03 Ept1 −4.45
Mamdc4 2.81 Tmsb15l −3
Plk3 2.68 Kdm4b −2.8
Table 3 Differentially expressed protein coding genes (mRNA)
showing the highest fold changes (in either direction) in kidney
samples of the Ins2Akita mice in the diabetic (D) and P78
treatment (T) groups (Continued)
Lars2 2.57 Selm −2.47
Sgk1 1.76 Cyp4a14 −2.22
Tmem252 1.75 Cyp24a1 −2.02
Adck5 1.72 Alox5ap −1.92
Psmd13 1.68 Etf1 −1.71
Chic2 1.67 Hba-a1 −1.54
Slc25a25 1.61 Odc1 −1.52




















A. All protein-coding genes with increased or decreased expression levels by
FC > (+/-)1.5 (q < 0.05) in diabetic relative to wt control B. All coding genes
upregulated or downregulated by P78 treatment with FC > =(+/-)1.5 (q < 0.05)
relative to diabetic controls. C. All coding genes with FC > (+/-)1.5 (q < 0.05)
that were reverted in their expression towards normal levels by P78 treatment
(TvD, early and late treatment). Genes are rank ordered by FC (positive or
negative values)
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increased expression (+2.06) with early treatment and
change in expression in the opposite direction (-1.41) with
late treatment, the other 15 genes were regulated in the
same direction by P78 and with similar FC in both diabetic
stages treated (Table 4B). Many differences in genes show-
ing expression changes were also observed between the
early and late stage diabetes treatments. For example in
early diabetes treatment increased levels of Ugt1a2 (+5.41
FC), S100a9 (+4.23 FC), Plk3 (+3.82 FC), and Lcn2 (+3.38
FC) and decreased levels of Cyp24a1 (-2.51 FC) and Tfpi2
(-1.76 FC), genes whose expression changes were not evi-
dent with late treatment using our cut off criteria. Others
that showed changes in gene expression with late stage dia-
betes treatment including Alox5ap (-5.18 FC), Etf1 (-2.48
FC), Psmd13 (+1.98 FC), and Adck5 (+1.89 FC) did not
show changes with early stage treatment.
Non-coding small RNAs (miRNA)
Diabetes and P78 also regulated a group of small non-
coding RNA precursor biotypes, with yet unknown or
speculative function but are generally believed to control
expression and biological function of coding genes.
Twenty nine of these with the greatest expression changes
(FC > (+/-)5.5 (q < 0.05) were identified in the diseased
kidney compared to wild-type controls (Table 5A) and in-
clude miRNA, snRNA, snoRNA, and pseudogene bio-
types. miRNAs highly regulated in DN with FC > =(+/-)20
(q < 0.05) include Mir1247 (-86.22), Mir142b (-42.04),
Mir1905 (+29.52), Mir196a-1 (+22.61), Mir27a (+20.80)
(Table 5A). From this analysis, we also identified a set of
small RNAs, categorized as miRNA by Gencode, that was
highly regulated by diabetes (DvC) and whose expression
levels were completely or partially reversed by P78 treat-
ment (TvD). These are rank ordered by FC (up/down) in
Table 5B. Of interest in the development and treatment of
DN are those miRNA regulated by diabetes whose
expression levels were complete reversed by P78 treat-
ment including Gm24083, Gm25953, and Gm25535,
GM25872, Mir1898, Gm25361, Mir7036, Mir7001, and
Mir3098. Others including Mir1247 (-86.22) and Mir142b
(-42.04) where expression changes in diabetes were not
significantly returned to normal levels by treatment. While
the functions of many of these sequences are still being
elucidated, they represent a class of RNAs that may be
useful in understanding the DN pathobiology and in de-
veloping treatments for the disease.
Biological function - pathways Ingenuity Pathway
Analysis (IPA)
IPA analysis shows that protein-coding genes regulated
by diabetes and returned to near normal levels by treatment
(Table 3C) are associated with key biological functions in-
cluding lipid metabolism, post translational modification,
endocrine and hematological functions, cell death and sur-
vival, and protein synthesis, all important processes associ-
ated with the disease (Fig. 6a). Many of these are also
associated with other pathologies including organismal in-
jury and abnormalities, cancer, developmental and heredi-
tary disorders (Fig. 6b)
IPA gene ontology algorithms and KnowledgeBase mining
identified several important canonical pathways enriched for
the differentially expressed genes (DEG) in our dataset. DEG
fell into one of several functionally relevant canonical path-
ways associated with diabetes and kidney pathology. Figure 7
shows the top pathways represented with FC > =(+/-)1.5
(q > 0.05) and Fig. 8, the percentage of genes regulated rela-
tive to those present in the IPA knowledgebase that are
assigned to a given pathway and the direction of their regu-
lation (red: upregulated; Green: downregulated) for diabetic
(DvC) and P78 treatment (TvD) groups (relative to wt con-
trols). The total number of genes assigned to a pathway in
the IPA KnowledgeBase is given to the right of each bar.
Fig. 5 PCR of pooled kidney samples (n = 7-13) from Control (C; wt), Diabetes (D), P78 treatment early stage diabetes (ET) and P78 treatment late
stage diabetes (LT). QRT-PCR (left) and RT-PCR (right) analyses confirm the trend of the rRNAseq data for regulation of a group of genes that were
modulated with FC > =(+/-)2 by both diabetes and P78 treatment. Wt controls (C, not indicated as bars in the graph) are set to 1. (DvC: #p ≤ 0.05;
##p ≤ 0.01; ###p ≤ 0.001; ETvD or LTvD: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)
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The open area of each bar represents genes in the pathway
that are not represented in our dataset. Pathways were rank-
ordered by IPA base on the significance of the directional
change (–log(p-value) and are limited to those enriched in
IPA KnowlegeBase.
The graph in Fig. 8a shows a striking trend in diabetes-
induced DEGs with mitochondrial dysfunction in the
diabetic group relative to wild type controls. The largest
functional cluster of genes modulated by diabetes was
represented in the mitochodrial dysfunction canonical
pathway. Approximately 50% of the 123 genes assigned
to this pathway were differentially expressed by diabetes
and ~48% of these were downregulated. The overall
trend observed from this analysis was that diabetes de-
creased expression of more kidney genes clustered in
these pathways (12/16) when compared to controls. In
three of these pathways associated with chronic renal
injury, renal failure, and renal inorganic phosphate
homeostasis, all genes were downregulated by diabetes
that were present in our kidney dataset.
P78 targeted some of the same pathways as diabetes but
fewer genes showed altered expression levels after treat-
ment relative to controls (Fig. 8b). For example, ~50% of
the genes in the mitochondrial pathway showed changes
in expression in the diabetes group relative to controls
while only ~5% showed altered expression in the treated
diabetes group relative to controls. Genes in the P78
treated diabetic mice represented in the cytochrome P-
450 and reversible glomerulonephritis associated pathways
were all downregulated compared to those in the same
pathway for non-treated mice. While those assigned to
the recovery from ischemic acute renal failure pathway
showed increased levels of expression after treatment
Table 4 Protein coding genes differentially expressed with the
highest positive or negative FC in kidney samples of the Ins2Akita
diabetic mice
A
ET vs D LT vs D
Gene Fold change Gene Fold change
Nhej1 −38.55 Nhej1 −37.33
Tceanc2 6.03 Ept1 −7.87
Ugt1a2 5.41 Tceanc2 5.48
S100a9 4.23 Alox5ap −5.18
Lars2 3.99 Cyp4a14 −4.74
Plk3 3.82 Mamdc4 3.78
Lcn2 3.38 Kdm4b −2.82
Ept1 −3.12 Etf1 −2.48
Kdm4b −2.79 Selm −2.37
Selm −2.58 Psmd13 1.98
Cyp24a1 −2.51 Adck5 1.89
Cyp27b1 2.33 Ugt1a6a 1.76
Arhgap27 2.22 Ndufaf1 1.71
Sgk1 2.22 Vps39 1.64
Fga 2.13 Rfxap 1.62
Tmem252 2.09 Chic2 1.61
C3 2.06 Erlin1 −1.61
Angptl4 2.05 Hacl1 1.59
Slc25a25 2.04 Hpd 1.56




















Table 4 Protein coding genes differentially expressed with the










The tables show only those genes that were significant and reliably expressed
with FC > =(+/-)1.72 (ET), FC > =(+/-)1.52 (LT) (q < 0.05) and those that were
regulated by both treatments (overlapping).These were rank-ordered by
highest numerical +/- FC values. A. P78 treatment administered at early (ET,
early treatment) or late (LT, late treatment) stage diabetes relative to diabetic
controls. 28 genes were regulated by treatment with P78 at the early stage of
diabetes and 20 by treatment at the late stage of diabetes. B. The table shows all
protein-coding genes that were regulated by P78 in the same direction (except
C3) at both stages of diabetes which represented ~50% of the genes
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compared to the non-treated diabetic mice. Since we pre-
viously showed that P78 significantly reduced physio-
logical and pathological changes in diabetic nephropathy
[24, 25] these target pathways and their associated genes
may give mechanistic clues to the disease.
Discussion
In this study we identified a set of transcriptome changes in
the kidney of the Ins2Akita mouse model of diabetic ne-
phropathy (DN) with and without PEDF-P78 peptide
treatment. Kidney samples were obtained from our re-
cently published studies in which we showed that con-
tinuous infusion of P78 reduced albuminuria, blood
urea nitrogen, and progression of DN [24, 25]. The re-
sults from this study provides a panel of biomarkers
that shed light into the DN pathology and validate the
use of P78 as a therapeutic approach for renal injury.
Using an RNAseq approach [35], we identified a panel
of genes dysregulated in DN. Genes showing the greatest
decrease in expression in DN include Srd5a2 (5 alpha
reductase), Aif1 (Allograft inflammatory factor 1), a protein
that modulate insulin secretion in prediabetic rats [36],
Angptl7 (angiopoietin-related protein 7), Thrsp (thyroid
hormone-inducible hepatic protein), and Ucp1 (thermoge-
nin), found in the mitochondrial membrane of brown adi-
pose tissue [37]. In addition, functional annotation using
Ingenuity Pathway analysis and KnowledgeBase re-
vealed the highest enrichment of DN regulated genes
in oxidation-reduction reaction and lipid biosynthesis
pathways including the genes Srd5a2, Scd1 (Stearoyl-CoA
desaturase), HSD17B11 (Estradiol 17-beta-dehydrogenase
11), FASN (Fatty acid synthase), DEGS2 (Delta(4)-desaturase,
sphingolipid 2), ALOX15 (Arachidonate 15-lipoxygenase),
and PECR (Peroxisomal trans-2-enoyl-CoA reductase)
(supplemental data). Scd1, for example, catalyzes the
rate-limiting reaction of monounsaturated fatty acid
synthesis [38] and is regulated by leptin, a key regulator
of obesity-linked diabetes, through insulin independent
mechanisms [39] while FASN deregulation is linked to
metabolic diseases and insulin-resistance [40]. While
clear associations between these genes and DN are not yet
elucidated, their involvement in important biochemical
pathways of insulin metabolism, oxidative stress, and obes-
ity, suggest they have important influences on renal injury.
We also identified genes whose expression in diabetic
animals was affected by P78 treatment. 12.2% (138/1129) of
all RNA transcripts showing abnormal expression in DN
were reverted back to partial or complete normal levels by
treatment. Because P78 is effective in reducing many of the
pathological features of DN [24, 25], we propose that this
core set of P78 targets may be responsible for the pathology
seen in DN and represent key druggable targets.
Non-homologous end-joining factor 1 (Nhej1), for ex-
ample, had the highest expression increase in DN (>30
fold compared with control) and the highest decrease
(>30 fold compared with diabetic) by both early and late
P78 treatments. Nhej1 encodes an essential repair factor
in double-stranded DNA breaks [41]. Its elevated expres-
sion may be a response to diabetes-induced DNA damage
in renal proximal tubule cells [42]. The protective role of
P78 in reducing assault on the kidney by diabetes-induced
DNA damage, may in turn, result in decreased levels of
Table 5 Differentially expressed precursor miRNAs including
Gms assigned as miRNA by Gencode with highest FC in kidney
samples of the Ins2Akita mice
A B
Gene Fold change Gene DvC TvD
Mir1247 −86.22 Gm24083 43.15 −45.45
Gm24083 43.15 Gm25953 34.53 −36.37
Mir142b −42.04 Mir1905 29.52 −5.19
Gm25953 34.53 Gm25535 −28.56 23.41
Mir1905 29.52 Gm27903 −26.25 11.75
Gm25535 −28.56 Mir196a‐1 22.61 −2.35
Gm27903 −26.25 Gm25738 −17.06 10.57
Gm23251 22.85 Gm25872 −16.27 23.35
Mir196a‐1 22.61 Gm28010 15.43 −3.08
Mir27a 20.80 Mir6991 14.82 −2.65
Mirlet7b 18.64 Mir6364 −12.80 8.06
Gm25738 −17.06 Gm27684 12.51 −1.86
Mir6386 16.74 Mir328 −11.78 8.56
Gm25872 −16.27 Mir1898 −9.23 9.49
Gm28010 15.43 Gm25361 −8.57 10.18
Mir6991 14.82 Gm23134 −6.45 1.80
Mir6981 13.64 Mir7036 −5.33 16.87
Mir6364 −12.80 Mir7001 −4.92 4.78
Gm27684 12.51 Mir3098 4.61 −3.51
Gm24515 11.93 Gm27768 −3.70 4.45
Mir328 −11.78 Gm25233 −3.70 4.45
Gm25297 11.09 Gm22734 −3.70 4.45
Mir1898 −9.23 Gm26043 2.96 −8.34
Gm25361 −8.57 Gm22721 −2.76 2.17
Gm27920 7.86 Gm25640 −2.43 6.59
Gm27512 7.53 Mir6363 −2.08 2.27
Gm28033 7.13 Gm25190 −1.93 2.33
Gm23134 −6.45 Mir27b −1.84 2.01
Gm23268 −5.97 Mir3082 −1.66 1.57
A. miRNAs regulated by diabetes with FC > =(+/-)5.97 (q < 0.05) relative to
control.Genes are listed by highest numerical FC values (positive or negative),
B. miRNAs with expression levels altered by diabetes that were reversed by
P78 treatment. Genes are listed by highest numerical FC values (FC > =+/-1.66,
q < 0.05) in DvC (first column) and the relative regulation values of these same
genes after treatment (TvD) given in the second column
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a b
Fig. 6 a. Biological functions associated with 12 target genes (Table 3C) regulated by diabetes that were completely reversed in their expression
to control levels by P78 treatment, b. Disease relatedness of these genes are shown with percentage indicating number of genes in each group
b
a
Fig. 7 Canonical pathways identified by Ingenuity pathway analysis (IPA) gene ontology algorithms for all significant and reliable DEG in the dataset. a.
DvC: diabetic Ins2Akita mouse kidney samples. b. TvD: kidney samples obtained from Ins2Akita mice after 6 weeks of continuous P78 infusion. Canonical
pathways are displayed along the x-axis and the –log(p-value), calculated by Fisher’s exact test right-tailed, on the y-axis. Threshold set to 1.5 indicates the
minimum significance level (–log(p-value). Height of the bars represents significance (probability that DEG in the dataset are associated with a canonical
pathway) with taller bars representing more significant associations. The ratio (orange points) indicates the number of DEG (FC > 1.5; q < 0.05) in the
diabetes and treatment datasets that map to a given canonical pathway divided by the total number of genes in that pathway within the IPA reference list
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Fig. 8 (See legend on next page.)
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Nhej1, thus, implicating genotoxicity as a mechanism in
renal injury.
Ept1 (Ethanolaminephosphotransferase 1) and Selm
(Selenoprotein M), genes related to the selenoprotein
gene family, were also in the group regulated by both
diabetes and P78. Ept1 is involved in the formation and
maintenance of vesicular membranes with relevance to
golgi function [43], while Selm codes for a selenocys-
teine containing protein that maintains redox balance
and is linked to obesity and amyloid beta aggregation in
the brain [44, 45]. Both genes were upregulated by dia-
betes with expression reversed by treatment. These
along with Txnrd1 (Thioredoxin reductase 1) which
plays a role in oxidative stress and hyperglycemic
events [46] form a cluster of genes with roles in selen-
ium metabolism and oxidative stress that may be linked
to renal damage. Ugt1a and Mamdc4, which were
downregulated and Cyp4a14 and Kdm4b, which were
upregulated in diabetes by 2-4 fold also had near
complete restoration of expression levels to control by
P78. Ugt1a genetic variants predict high risk for Type 2
diabetes mortality [47] while Mamdc4 deletions are as-
sociated with a group of inflammatory axial diseases
[48]. Cyp4a14 KO mice have increased hypertension
and develop diabetic nephropathy when treated with
streptozotocin (STZ) compared to wild-type treated
with STZ [49] and Kdm4b, a lysine demethylase, plays
a role in regulating chromatin structure [50]. Given
their regulation by both diabetes and P78 treatment,
and their association with important metabolic func-
tions, these genes are candidate biomarkers with clin-
ical relevance in DN.
We also noted that expression changes in some genes
were unique to early or late stage diabetes suggesting
that some pathological events/pathways in the diabetic
kidney transcriptome are stage-specific. On the other
hand since ~64% of the gene changes in the kidney were
similar in the two stages of diabetes, it can be argued
that most of the pathology in DN are initiated at a very
early stages of the disease. Intervention at either stage
with P78 is likely to reduce diabetic insult to the kidney,
as we have previously shown [25], through its regulation
of these genes. Genes regulated by diabetes and not re-
versed by treatment are likely to be important as well
and may be clustered in yet unknown pathways, which
could represent metabolic responses to hyperglycemia
that may or may not result in deleterious pathological
consequences.
IPA analysis showed mitochondrial dysfunction as the
most significantly regulated pathway by diabetes. It was
enriched with the highest number (61 genes; 7%) of
kidney genes showing expression changes in diabetes.
After treatment those numbers were reduced by ~85-
90% relative to controls. This analysis strongly implicates
mitochondrial dysfunction as a key event in the
development of DN, regardless of whether it is a primary
or secondary target of diabetes, and provides unequivo-
cal evidence for the utility of P78 treatment in its man-
agement. In addition, since treatment reversed several
diabetes-induced changes in both early and late stage
pathology, the P78 peptide has broader clinical relevance
for the disease. Other canonical pathways enriched by
diabetes-regulated genes were fatty acid metabolism, Nrf2-
mediated oxidative stress, oxidative stress, and those impli-
cated in renal injury, many of which were less populated
after treatment.
Non-coding transcripts including miRNA, snRNA, and
snoRNA, were some of the most highly regulated mole-
cules in the diabetic kidney. Small RNAs are known to con-
trol the transcriptome, kinome and proteome domains and
are involved in normal and pathological gene regulation.
Many that showed changes in expression with diabetes
were also reversed in the direction of these changes after
P78 treatment suggesting that members of this group, with
functions yet unknown, are important in development and
progression of the disease as well as in understanding its
future management.
The Ins2Akita mouse is a good model of Type I diabetes.
However, it will be interesting to see how many of the
diabetes-induce gene expression changes we have docu-
mented are common to Type II diabetes and how many
are found in other diabetic complications such as diabetic
retinopathy.
Conclusion
Diabetes altered expression of a group of coding and
non-coding genes in the D2.B6-Ins2Akita/MatbJ model of
DN. Treatment of diabetic mice with P78 reversed ex-
pression of a specific subset of these genes. These may
be key regulators of diabetes-induced kidney dysfunction
(See figure on previous page.)
Fig. 8 Regulation profile of genes in the canonical pathways most significantly associated with DEG in our RNAseq dataset. a. Diabetic Ins2Akita
kidney samples relative to control. b. P78-treated diabetic Ins2Akita kidney samples relative to control. The stacked bars show the percentage of
genes (y-axis) distributed according to the direction of gene regulation changes in each canonical pathway (x-axis). Genes that were significantly
up-regulated in our dataset are shown in red, those that were down-regulated in green, and those found in the IPA reference gene set that had
no overlap with our dataset represented as open bars. The numerical value at the right of each canonical pathway bar indicates the total number
of genes present in the IPA Knowledge base for that pathway. The orange line represents the significance of the directional change (–log(p-value)
calculated by adjusting the right-tailed Fisher’s Exact t-test p-values using the Benjamini-Hochberg method
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as P78 was previously shown to reduce physiological and
pathological features of DN. While the precise roles of
these genes in DN pathology remain unclear, they give
initial clues to how the disease develops. Our study
provides a set of unique biomarkers to be exploited in
DN and other diabetic complications and suggests that
the PEDF-P78 peptide holds promise for the manage-
ment of this disease.
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